These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

195 related items for PubMed ID: 37781359

  • 1. Case Report: Non-negligible Epstein-Barr virus-associated posttransplant lymphoproliferative disorders in a lung transplant recipient.
    Hu J, Yu YW, Han DS, Li XJ, Zhang YQ, Cai HL, Xiao YH, Zheng X.
    Front Immunol; 2023; 14():1244534. PubMed ID: 37781359
    [Abstract] [Full Text] [Related]

  • 2. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorders and Epstein-Barr virus DNAemia in a cohort of lung transplant recipients.
    Baldanti F, Rognoni V, Cascina A, Oggionni T, Tinelli C, Meloni F.
    Virol J; 2011 Sep 05; 8():421. PubMed ID: 21892950
    [Abstract] [Full Text] [Related]

  • 4. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
    Omar H, Hägglund H, Gustafsson-Jernberg A, LeBlanc K, Mattsson J, Remberger M, Ringdén O, Sparrelid E, Sundin M, Winiarski J, Yun Z, Ljungman P.
    Transpl Infect Dis; 2009 Oct 05; 11(5):393-9. PubMed ID: 19497070
    [Abstract] [Full Text] [Related]

  • 5. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb 05; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 6. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ, Perrine SP, Faller DV.
    Transpl Infect Dis; 2001 Sep 05; 3(3):177-85. PubMed ID: 11493400
    [Abstract] [Full Text] [Related]

  • 7. Late-onset posttransplant Epstein-Barr virusrelated lymphoproliferative disease after cord blood transplantation for chronic active Epstein Barr virus infection: A case report.
    Yamamoto M, Shindo M, Funayama T, Sumi C, Saito T, Toki Y, Hatayama M, Imadome KI, Mizukami Y, Okumura T.
    Medicine (Baltimore); 2022 Mar 25; 101(12):e29055. PubMed ID: 35357349
    [Abstract] [Full Text] [Related]

  • 8. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L, Frankel C, Bush EJ, Neely ML, Pavlisko EN, Mokrova IL, Luftig MA, Palmer SM.
    J Med Virol; 2021 Aug 25; 93(8):5040-5047. PubMed ID: 33704812
    [Abstract] [Full Text] [Related]

  • 9. Diagnostics of the Epstein-Barr Virus Before and After Lung Transplantation in a Patient With Developing Posttransplant Lymphoproliferative Disease: A Case Report.
    Stanjek-Cichoracka A, Łaszewska A, Zawadzki F, Kobylska A, Urlik M, Stącel T, Ochman M.
    Transplant Proc; 2022 May 25; 54(4):1180-1182. PubMed ID: 35461713
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders in Cystic Fibrosis Lung Transplant Recipients: A Case Series.
    Mendogni P, Henchi S, Morlacchi LC, Tosi D, Nosotti M, Tarsia P, Gregorini AI, Rosso L.
    Transplant Proc; 2019 May 25; 51(1):194-197. PubMed ID: 30655153
    [Abstract] [Full Text] [Related]

  • 11. Prospective Epstein-Barr virus-related post-transplant lymphoproliferative disorder prevention program in pediatric allogeneic hematopoietic stem cell transplant: virological monitoring and first-line treatment.
    Chiereghin A, Prete A, Belotti T, Gibertoni D, Piccirilli G, Gabrielli L, Pession A, Lazzarotto T.
    Transpl Infect Dis; 2016 Feb 25; 18(1):44-54. PubMed ID: 26574232
    [Abstract] [Full Text] [Related]

  • 12. T-cell posttransplant lymphoproliferative disorders after allogeneic hematopoietic cell transplantation.
    Kuno M, Ito A, Maeshima AM, Taniguchi H, Tanaka T, Inamoto Y, Kurosawa S, Kim SW, Fukuda T.
    Int J Hematol; 2020 Aug 25; 112(2):193-199. PubMed ID: 32472530
    [Abstract] [Full Text] [Related]

  • 13. Epstein-Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report.
    Dutta R, Miao SY, Phan P, Fernandez-Pol S, Shiraz P, Ho D, Mannis GN, Zhang TY.
    J Med Case Rep; 2021 Mar 28; 15(1):170. PubMed ID: 33773605
    [Abstract] [Full Text] [Related]

  • 14. Epstein-Barr virus-associated risk factors for post-transplant lymphoproliferative disease in pediatric liver transplant recipients.
    Quintero Bernabeu J, Juamperez J, Mercadal-Hally M, Larrarte King M, Gallego Melcon S, Gros Subias L, Sábado Álvarez C, Soler-Palacin P, Melendo Pérez S, Esperalba J, Navarro Jiménez A, Garrido Pontnou M, Camacho Soriano J, Hidalgo Llompart E, Bilbao Aguirre I, Charco Torra R.
    Pediatr Transplant; 2022 Sep 28; 26(6):e14292. PubMed ID: 35466492
    [Abstract] [Full Text] [Related]

  • 15. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
    Aris RM, Maia DM, Neuringer IP, Gott K, Kiley S, Gertis K, Handy J.
    Am J Respir Crit Care Med; 1996 Dec 28; 154(6 Pt 1):1712-7. PubMed ID: 8970360
    [Abstract] [Full Text] [Related]

  • 16. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.
    Walti LN, Mugglin C, Sidler D, Mombelli M, Manuel O, Hirsch HH, Khanna N, Mueller N, Berger C, Boggian K, Garzoni C, Neofytos D, van Delden C, Hirzel C, Swiss Transplant Cohort Study (STCS)Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland..
    Am J Transplant; 2021 Jul 28; 21(7):2532-2542. PubMed ID: 33289340
    [Abstract] [Full Text] [Related]

  • 17. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
    Fellner MD, Durand KA, Solernou V, Bosaleh A, Balbarrey Z, García de Dávila MT, Rodríguez M, Irazu L, Alonio LV, Picconi MA.
    Rev Argent Microbiol; 2016 Jul 28; 48(2):110-8. PubMed ID: 27157146
    [Abstract] [Full Text] [Related]

  • 18. Epstein Barr viral load monitoring by quantitative PCR in renal transplant patients.
    Merlino C, Cavallo R, Bergallo M, Giacchino F, Bollero C, Negro Ponzi A, Cavallo G.
    New Microbiol; 2003 Apr 28; 26(2):141-9. PubMed ID: 12737195
    [Abstract] [Full Text] [Related]

  • 19. [Dynamic monitoring of plasma Epstein-Barr Virus DNA load can predict the occurrence of lymphoproliferative disorders after haploidentical hematopoietic stem cell transplantation].
    Chen J, Sun YQ, Xu LP, Zhang XH, Liu KY, Mo XD, Cheng YF, Huang XJ, Wang Y.
    Zhonghua Xue Ye Xue Za Zhi; 2023 Apr 14; 44(4):284-288. PubMed ID: 37356996
    [Abstract] [Full Text] [Related]

  • 20. Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipients.
    Riddler SA, Breinig MC, McKnight JL.
    Blood; 1994 Aug 01; 84(3):972-84. PubMed ID: 8043879
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.